Mir129-2 is a microRNA that has been shown to play important roles in various biological processes and diseases. It has been associated with regulating gene expression, and its dysregulation is linked to cancer development [1,2,3,6,7,8,9,10]. It targets genes such as SOX4, and is involved in pathways related to cell survival, migration, and angiogenesis, potentially through its influence on genes like NG2/CSPG4 [2,4]. In pancreatic beta-cell regulation, miR-129-2 can control the fate of beta-cell precursors by regulating TMEM219 expression [5].

In cancer research, studies on human cancer tissues have revealed significant findings. In gastric cancer, the MIR129-2 gene was hypermethylated in tumoral tissues compared to normal tissues, suggesting its involvement in gastric cancer development [1]. In colorectal cancer, hypermethylation of MIR129-2 promoter was associated with upregulated SOX4 mRNA expression and metastasis [2]. In hematological malignancies, MIR129-2 was frequently methylated in lymphoid malignancies, leading to its silencing, and in chronic lymphocytic leukemia (CLL), its methylation was associated with inferior survival [3]. It has also been investigated in esophageal, prostate, non-small cell lung, and breast cancers, with methylation changes of MIR129-2 being potential biomarkers for detection and diagnosis [6,7,8,9,10].

In conclusion, Mir129-2 is a crucial microRNA involved in gene regulation with implications for various biological processes, especially in the context of cancer. The research on its methylation status in different cancers, as observed in human tissue samples, highlights its potential as a biomarker and therapeutic target, contributing to a better understanding of cancer development mechanisms.